InvestorsObserver
Sign Up Login

GRNA Greenlight Biosciences Hldgs Pbc

$2.30 $-0.02 (-0.86%)
Add to Watchlist Compare
Overall

GRNA Stock Analysis Overview

What this means: Greenlight Biosciences Hldgs Pbc (GRNA) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives GRNA a rank of 8. Our methodology considers analysis of the company's financial situation and how it has traded recently. GRNA rank of 8 means that it ranks below 92% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

GRNA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

GRNA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

GRNA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

GRNA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

GRNA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

GRNA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

GRNA Stock Analysis Overview

What this means: Greenlight Biosciences Hldgs Pbc (GRNA) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives GRNA a rank of 8. Our methodology considers analysis of the company's financial situation and how it has traded recently. GRNA rank of 8 means that it ranks below 92% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full GRNA report

GRNA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

GRNA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

GRNA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

GRNA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

GRNA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

GRNA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Greenlight Biosciences Hldgs Pbc (GRNA) Analyst Forecast

GRNA Price, Volume, Earnings, and Dividend Date

  • Last Price $2.30
  • Previous Close $2.32
  • Change $-0.02
  • Open $2.34
  • Volume 280,377
  • Avg. Volume (100-day) 530,379
  • Market Cap 283,358,165
  • Days Range 2.24 - 2.34
  • 52-week Range 1.55 - 15.8
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 11/21/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.262
  • PEG Ratio —

Greenlight Biosciences Hldgs Pbc (GRNA) Company Description

GreenLight Biosciences Inc is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.

Greenlight Biosciences Hldgs Pbc (GRNA) Stock Chart

View Interactive GRNA chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
G1 Therapeutics Inc (GTHX) (GTHX) $12.41
Ardelyx Inc (ARDX) (ARDX) $1.34
Satsuma Pharmaceuticals Inc (STSA) (STSA) $5.30
Pliant Therapeutics Inc (PLRX) (PLRX) $21.02
Liquidia Corp (LQDA) (LQDA) $5.52
Axsome Thera (AXSM) (AXSM) $45.33
Fireman B.V. (IFRX) (IFRX) $2.71
Wave Life Sci Ord Sh (WVE) (WVE) $3.54
Concert Pharmaceutic (CNCE) (CNCE) $6.60
Capricor Therap (CAPR) (CAPR) $6.10